Healthcare’s COVID-19 financial crisis is accelerating digital transformation the same way the health crisis catalyzed clinical transformation.

Healthcare’s patient revenue cycle systems have been encumbered by a variety of inefficiencies. Digital transformation corrects these, thereby reducing costs and improving resiliency – all while setting the stage for longer-term revenue improvement – Kevin Fleming, CEO, Loyale Healthcare

LAFAYETTE, Calif. (PRWEB)
June 11, 2020

The gravity of COVID-19’s financial impact on healthcare providers is difficult to overstate. According to a release from healthcare consulting firm Kaufman Hall, hospital operating margins “plummeted 282% in April compared to the previous year, 326% below budget.” April was the first full month to bear the brunt of COVID-19-related disruptions to costs and revenue. And according to the analysis, “The damage has been severe, with median operating margins falling to -29%.”

“April was the worst month ever for hospital finances,” said Jim Blake, managing direct at Kaufman Hall. “Our nation’s hospitals are in a perilous position. They are serving as the frontlines of our battle against this virus, but the pandemic is threatening their fundamental financial viability at a time when we need them most. The road back to recovery will be difficult and our healthcare system will be forever changed.”

The early stages of that change are already underway. Indeed, some healthcare systems and hospitals had already included a number of transformational initiatives in their strategic plans. The COVID-19 crisis has motivated many to accelerate what had been long-term ideas into immediate operating imperatives. Telehealth is just one example. Necessitated by requirements for contactless patient engagement and supported by revised reimbursement policies from Medicare and Medicaid, digital patient engagement has been fast-tracked by providers everywhere to manage costs, boost productivity and respond to patient expectations.

This technology-enabled transformation extends to healthcare financial management, where the need for transformation is more acute than ever before. According to a Black Book Research release titled Accelerated Digital Transformation Key to Recovery for Healthcare CFOs,” when more than 1,800 healthcare CFOs and other leaders were surveyed about the effectiveness of their existing systems, “93% of all provider respondents stated that missing capabilities and redundant or conflicting systems were identified in Q2 2020 to drive immediate financial systems rationalization and acquisitions.”

Healthcare CFOs recognize that the digital transformation of financial systems is an imperative. And although, “100% of all CFOs surveyed recognize they will experience a significant revenue decline this fiscal year and they will have to adjust spending accordingly, only 12% expect they will need to cut or defer spending on their financial systems’ digital transformation.”

“It would seem most CFOs understand what the pandemic has proved is the need to speed up digital transformation initiatives to not only survive but to prosper in the new normal,” said Doug Brown, President of Black Book Research in their announcement. “For CFOs eager to expedite their organization’s digital transformation, the standardization and simplification leaders want in their back-end processes are allowing for less complicated, faster adoption despite the times.” In fact, the research goes on to report, “Eighty-one percent of surveyed CFOs and senior leaders revealed the absolute and immediate need for digital transformations for long term survival of their healthcare organization.”

One Loyale Healthcare client, an industry-leading provider of financial and operating solutions across the country, has made digital financial transformation its top priority. By working with Loyale to shift provider processes away from costly, labor-intensive systems requiring person-to-person contact, they are finding that patient safety and revenue cycle performance don’t have to come at the expense of patient satisfaction. This vision for digital patient financial engagement was an important part of why Loyale was chosen as the digital patient engagement platform for one of the nation’s largest healthcare system.

Traditional healthcare financial systems have become an operational liability, especially now in the midst of the COVID-19 crisis. Loyale’s clients are looking to reduce their costs while improving the delivery of care in a socially-distanced, disease-conscious environment and they want to do it now. Contactless digital patient financial engagement is the only path that offers the efficiencies providers need and the experiences patients demand.

Understanding the New Normal for healthcare financial management

Before COVID-19 lit a fire under many hospitals’ and health systems’ transformational initiatives, patient revenue cycle systems were encumbered by a variety of inefficiencies. Digital transformation corrects these, thereby reducing costs and improving resiliency – all while setting the stage for longer-term revenue improvement. The comparison below illustrates some of these inefficiencies’ outcomes and the results that can be achieved as new approaches are embraced.

Pre-COVID-19    / Post COVID-19: The New Normal

• High Payroll or Outsource cost structure / Low-cost, tech-enabled cost structure
• Difficult to scale, either up or down / Instantly adapts to meet demand
• Digital patient engagement < 10% / Digital engagement of 60 to 80%
• High patient collection costs / Two-thirds reduction in cost or more
• Financial & regulatory compliance, costs / Outsourced – no staff time or expense
• Low patient collections, 20%+ bad debt / Reduce patient bad debt by 20% or more

Up to now, most hospitals and health systems have relied on large teams of staffed and outsourced personnel to manage patient financial interactions. The patient’s financial journey, from the point of engagement through treatment and finally into billing and payment – is affected by multiple systems, many of which have customarily been performed on site, face to face. Additionally, many of these systems don’t talk to each other, requiring even more work and creating opportunities for error. Finally, this disjointedness has made it impossible for even the most sophisticated providers to really understand how their patient revenue cycle systems are performing.

Alternatively, digital patient financial engagement is completely integrated, not only with other revenue cycle systems, but with other key healthcare systems such as Electronic Health Record (EHR) and merchant services. Perhaps most important of all, digital patient engagement incorporates the best qualities of proven digital providers in other industries to engage and delight patients who have become accustomed to finding information and doing business online. Its superior integration from end to end throughout the patient financial journey helps assure that healthcare CFOs and other leaders know exactly what’s working and what isn’t. This is crucial business intelligence that finally makes it possible to make well informed decisions about what to do next.

Turning Trauma into Transformation

The COVID-19 crisis has left a wake of financial damage across the healthcare industry. The severity of that damage is discouraging to say the least, and overcoming it won’t be easy. But cause for optimism is clearly evident throughout the industry’s remarkable response to the crisis. From creative new techniques for remote triage to satellite ICUs assembled and staffed in days instead of years to 3D-printed throat swabs to improve access to testing, America’s healthcare system has already demonstrated an astounding ability to adapt and transform. The industry’s continued commitment to digital transformation will be a fundamental component of its successful transition into healthcare’s new normal. We at Loyale are honored to be a part of it.

Kevin Fleming is the CEO of Loyale Healthcare

About Loyale

Loyale Patient Financial Manager™ is a comprehensive patient financial engagement technology platform leveraging a suite of configurable solution components including predictive analytics, intelligent workflows, multiple patient financing vehicles, communications, payments, digital front doors and other key capabilities.

Loyale Healthcare is committed to a mission of turning patient responsibility into lasting loyalty for its healthcare provider customers. Based in Lafayette, California, Loyale and its leadership team bring 27 years of expertise delivering leading financial engagement solutions for complex business environments. Loyale currently serves approximately 12,000 healthcare providers across 48 states. Loyale is proud to have an enterprise-level strategic partnership with Parallon which includes the deployment of Loyale’s industry leading technology at all HCA hospitals and Physician Groups.

Share article on social media or email:

The entire Aniara line is available for purchase at http://www.aniara.com.

WEST CHESTER, Ohio (PRWEB)
June 11, 2020

Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today’s highest standards for product quality and cost-efficient delivery.

For Research Use Only. Not for Use in Diagnostic Procedures.

T cell ELISPOT assays are extremely effective for COVID-19 vaccine research. Because Human and monkey research is critical in the COVID-19 field, IFN-gamma T cell ELISPOT assays are an attractive tool to determine the number of COVID-specific IFN-gamma producing T cells in the circulation of human and non-human primates.

A cytokine assay that has also been reported to be important for COVID-19 research is the IL-6 ELISA (cytokine ELISA kit).

ACT230-PR5 Human IFN-γ ELISPOT kit click here for more information

ACT121-PR5 Monkey IFN-y ELISPOT kit click here for more information

ACT640-20 Human IFN- IFN-y ELISPOT antibody pair click here for more information

ACT605-20 Monkey IFN-γ ELISPOT Antibody Pair click here for more information

ACT205A Human IL-6 ELISA click here for more information

The entire Aniara product line is available for purchase at http://www.aniara.com. The Company distributes products in North America, Central America, South America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

Share article on social media or email:

SITC logo

“Thanks to the generous support of our industry partners, SITC is able to support promising areas of research conducted by these early career investigators and future leaders within the cancer immunotherapy field,” said SITC President Mario Sznol, MD.

MILWAUKEE (PRWEB)
June 11, 2020

The Society for Immunotherapy of Cancer (SITC) is pleased to announce the recipients of six fellowships and a new award, which support the next generation of cancer immunotherapy and tumor immunology experts through dedicated funding of novel research.

This year’s awards include:

SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship, a two-year, $200,000 award; SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship, a one-year, $100,000 award; SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship, a one-year, $100,000 award; SITC-Merck Cancer Immunotherapy Clinical Fellowship, a one-year, $100,000 award; SITC-Genentech Women in Cancer Immunotherapy Fellowship, a one-year, $50,000 award; SITC’s Holbrook Kohrt, MD, PhD, Cancer Immunotherapy Translational Memorial Fellowship (sponsored by Genentech), a one-year, $50,000 award; and the SITC-NanoString Technologies Spatial Profiling Award, access to NanoString Technologies’ spatial profiling technology to further research.

SITC’s Forward Fund, established to advance important new findings from the laboratory into clinical trials, has committed more than $4 million in funding to deserving early career scientists in the field of cancer immunotherapy.

“Thanks to the generous support of our industry partners, SITC is able to support promising areas of research conducted by these early career investigators and future leaders within the cancer immunotherapy field,” said SITC President Mario Sznol, MD. “This is an investment in the future of our field that we hope will lead to new immunotherapy approaches and better outcomes for patients.”

The 2020 SITC Fellowships and Award recipients are:

SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship

Awardee: Li Qiang, PhD

Institution: Dana-Farber Cancer Institute, Harvard Medical School

Project Title: “Signaling pathways in tumoricidal macrophages in pancreatic cancer”

Award Amount: $200,000 (two year)

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship

Awardee: Suman Paul, MBBS, PhD

Institution: Johns Hopkins School of Medicine

Project Title: “T Cell receptor variable gene targeting for T cell cancer immunotherapy”

Award Amount: $100,000 (one year)

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Awardee: Jacob Kaufman, MD, PhD

Institution: Duke University Medical Center

Project Title: “Strategies to overcome immunotherapy resistance in LKB1 and KEAP/NRF2 mutated NSCLC: modulating ferroptosis to restore immune sensitivity”

Award Amount: $100,000 (one year)

SITC-Merck Cancer Immunotherapy Clinical Fellowship

Awardee: Joseph Clara, MD

Institution: National Institutes of Health (NIH)

Project Title: “CRISPR-Cas9-based gene editing to enhance cytotoxicity of natural killer cells against multiple myeloma”

Award Amount: $100,000 (one year)

SITC-Genentech Women in Cancer Immunotherapy Fellowship

Awardee: Natalie Vokes, MD

Institution: Dana-Farber Cancer Institute

Project Title: “Dissecting the molecular mediators of treatment response and resistance evolution in NSCLC”

Award Amount: $50,000 (one year)

SITC’s Holbrook Kohrt, MD, PhD Cancer Immunotherapy Translational Memorial Fellowship (Sponsored by Genentech)

Awardee: Kipp Weiskopf, MD, PhD

Institution: Whitehead Institute for Biomedical Research

Project Title: “Engaging macrophages to eliminate cancers with driver mutations”

Award Amount: $50,000 (one year)

SITC-NanoString Technologies Spatial Profiling Award

Awardee: Todd Triplett, PhD

Institution: University of Texas Dell Medical School

Project Title: “Determining the interplay between T-ALL and the immune system in distinct organs by digital spatial profiling”

Award: Access to NanoString Technologies’ spatial profiling technology to further research.

This year’s SITC Fellowships and Award were made possible through the generosity of Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Genentech, Inc., Merck and NanoString Technologies. The fellowship and award recipients will be honored during a ceremony at the society’s 35th Anniversary Annual Meeting, at the Gaylord National Hotel & Convention Center in National Harbor, Md.

To learn more about current and past SITC Fellowship and Award recipients, visit the society’s website, SITC Cancer Immunotherapy CONNECT.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Xtalks Life Science Webinars

Treiber and Rosen will address current best practices that enhance vaccine trials performance, such as including experienced sites in protocol development and how to focus site selection to maximize patient numbers across fewer sites for reduced variability.

TORONTO (PRWEB)
June 11, 2020

Will COVID-19 spur disruptive innovation in vaccine studies? The current pandemic has put a bright spotlight on vaccine trials, showing why it’s never been more urgent for robust and thoughtful vaccine trial designs that can be executed efficiently and nimbly. Typically shorter in duration relative to other trials, vaccine trials can cause an increased pressure to plan and execute adeptly.

Treiber and Rosen will address current best practices that enhance vaccine trials performance, such as including experienced sites in protocol development and how to focus site selection to maximize patient numbers across fewer sites for reduced variability. They will detail operational guidance like abbreviate ICFs for rapid pre-screening, pre-emptive measures to accelerate enrollment and operational efficiencies that can improve the speed and quality of vaccine trials. Historical case studies (Zika, Dengue, Chikungunya) will be discussed to demonstrate how these changed the approach to subsequent trials.

Each trial presents its own specific challenges. How will the current pandemic inform, adapt, or completely alter some of these proven strategies? Current events put into sharper focus the need for streamlined, accessible technologies that can make vaccine trials quicker, easier and more patient-centric.

Can tools such as ePRO diaries, telemedicine, HIPAA-compliant virtual systems and more aid in delivering results faster while maintaining quality? The presenters will explore these topics and provide practical insights on how vaccine trial planning and execution can evolve moving forward.

Join Scott Treiber, PhD, MBA, Vice President, Strategic Development, Synteract and Jeffrey Rosen, MD, Chief Medical Officer, Alliance of MultiSpecialty Research (AMR) in a live webinar on Tuesday, June 30, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Addressing the Rapidly Evolving Vaccine Development Landscape.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.

For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.

Share article on social media or email:

Xtalks Life Science Webinars

In this webinar, our panel of experts share examples and lessons learned during the COVID-19 window and explore how those lessons can drive meaningful change over the next 12 months

TORONTO (PRWEB)
June 11, 2020

Oncology trials always come with their share of complexities and challenges. Since its onset, COVID-19 has had the industry’s undivided attention, with clinical trial professionals adapting clinical trial operational plans to accommodate. From data integrity to participant recruitment and retention, our industry has temporarily reconsidered long-held habits. As the world begins to relax restrictions, what are the lessons learned that can catapult us into the next innovation in trial operations for good?

In this webinar, our panel of experts share examples and lessons learned during the COVID-19 window and explore how those lessons can drive meaningful change over the next 12 months including:

• 
  Leveraging technology to maximize risk and quality oversight
• Maximizing the patient experience and patient retention
• Designing trials to collect the data we need
• Managing missing data and redesigning analyses to account for anomalies like COVID

Join Dannelle Palmer, VP Clinical Operations, OncoBay, Mara Holinger, PhD, RAC, VP Regulatory Affairs, Veristat and Brendan Merrick, Sr. Clinical Data Manager, Veristat in a live webinar on Tuesday, June 23, 2020 at 12pm EDT (5pm BST/UK).

For more information or to register for this event, visit Methods for Minimizing the Disruption of Oncology Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

DALLAS (PRWEB)
June 11, 2020

In light of COVID-19, The Trade Group—an award-winning, event marketing and experiential design firm—recently pivoted from its core business of designing and building trade show exhibits to creating products people and organizations need in a post-pandemic world. Along with launching COVID-19 custom design and fabrication solutions for corporate interiors, restaurants, salons and other retail businesses, the company began manufacturing high-quality PPE face shields for front line workers in April.

The Trade Group’s new low-cost, high-quality PPE face shields were designed to protect the users entire face from spray, splatter and droplets. The shields feature a thick comfort band that absorbs sweat and provides ample space for eyeglasses or safety goggles beneath the shield. In addition, the shields can be easily cleaned with disinfectant and reused.

The decision to manufacture face shields at The Trade Group’s Carrolton, Texas headquarters was prompted by a huge demand for PPEs, which have been desperately needed by the nation’s healthcare workers since the pandemic began.

According to Robin Barhydt, Senior Design Consultant at The Trade Group, the company was uniquely positioned to pivot its manufacturing operations from trade show exhibits to face shields. “When COVID-19 became a reality in the U.S., the live event industry came to a halt. In that sink or swim environment, our creative and resourceful team decided to swim. Not only did we have the capacity to manufacture the shields, our team was also able to quickly acquire the resources needed to make PPEs, so we could get them out in the field right away.”

The Trade Group also decided to donate thousands of face shields to individuals and organizations that needed them right away. “We really wanted to do our part to help support and protect healthcare workers who were on the front lines. Time was of the essence, so we donated facial shields to those organizations that were in dire need,” Barhydt says.

Several healthcare organizations and workers received the face shields, including Brandi Carney BSN, RN Operating Room Manager, Baylor, Scott & White Surgicare Denton. Carney helped out at a Brooklyn, New York hospital in the midst of the COVID-19 crisis on the east coast.

According to Carney, “We were lucky to have the shields that were provided to us by The Trade Group. Most workers at the hospital that I was assigned to in Brooklyn only had one at the most. The risk of reusing them is dangerous if not sanitized correctly. We didn’t have to worry as were able to use a new protective face shield every shift thanks to The Trade Group.”

To learn more about The Trade Group’s affordable PPE face shields or corporate interior design and fabrication services for modifying workplaces to align with COVID-19 safety directives, please call 800-343-2005 or visit the COVID-19 resources page on The Trade Group’s website.

ABOUT THE TRADE GROUP:

The Trade Group is an award-winning, full-service event marketing and creative design firm, specializing in trade shows, esports events and activations, corporate events, brand activations, retail merchandising, commercial graphics and experiential solutions. Since 1986, the company’s team of live event, design and engineering experts has helped thousands of clients amplify their brands and successfully navigate a wide range of events and experiences. Clients rely on The Trade Group for: event ideation, creation and production; esports expertise; exhibit design and fabrication; graphic design and production; strategic marketing solutions; technology integration and more.

Press Contact:

Becca Richardson

Marketing Manager

brichardson@tradegroup.com

Share article on social media or email:

Patients as Partners US

“Relaunching on a virtual platform allows for more involvement from patients, biopharma, advocacy, academia and other stakeholders globally to demonstrate how patient engagement gets done,” Kate Woda, Conference Director, Patients as Partners US

NEW YORK (PRWEB)
June 11, 2020

The Conference Forum is pleased to announce the relaunch of the 7th annual Patients as Partners US conference in a live virtual format on August 19-21, 2020.

Patients as Partners US is the first conference in the US guided by patients with Pharma R&D executives and FDA to demonstrate how patient involvement gets implemented throughout the medicines development cycle in order to drive greater efficiencies in getting therapeutics to patients faster.

The event is co-chaired by Jamie Troil Goldfarb, a cancer veteran and advocate; Marilyn Metcalf, PhD, Senior Director, Patient Engagement, GSK; and Pablo Graiver, VP, Patient Engagement Digital Strategy, IQVIA.

It features representation from three FDA agencies, who will provide patient engagement guidance updates and new efforts: Anindita Saha, Director of External Expertise and Partnerships (EEP), CDRH; Captain Robyn Bent, Patient Focused Drug Program Director, CDER, FDA; and Karen Jackler, Patient Engagement Program Manager, CDER.

“Relaunching on a virtual platform allows for more involvement from patients, biopharma, advocacy, academia and other stakeholders globally to demonstrate how patient engagement gets done,” said Kate Woda, the Patients as Partners US conference director. The virtual format expands the program over three, shorter and more manageable days that allow for more discussion and engagement opportunities.

Keynote Speakers will be addressing the following topics:

Joanne Waldstreicher, MD, CMO, Johnson & Johnson will provide her perspective, as Johnson & Johnson’s Chief Medical Officer, on Making the Patient Experience Central to Business Strategy and Purpose.

Jeff Borghoff, Alzheimer’s Patient Advocate, will provide Insights into His Experience in the Biogen/Eisai Alzheimer’s Trial.

Ronnie Sharpe, Cystic Fibrosis Advocate, will be providing Clinical Trial Experiences as a CF Patient and Insights on Trial Disruptions from COVID-19.

Darryl Sleep, MD, SVP, Global Medical and CMO, Amgen will offer a CMO’s Perspective on Patient-Centric Research & Building a Culture of Patient Centricity.

Barry Greene, President, Alnylam Pharmaceuticals, will speak about Partnering with Advocacy to Help Patients with Clinical Trial Enrollment, Disease Education and Access to Treatments.

Ken Getz, MBA, Director and Associate Professor / Founder and Board Chair, Tufts CSDD/CISCRP, will offer New Data on Patient Preferences and Experiences to Inform Patient Engagement Strategies and Tactics.

Cornerstone speaker, Leah Fine, Senior Director, Excellence in Screening and Care, GO2 Foundation for Lung Cancer, will provide an Update on the Centers of Excellence Program and Integrating Data into Annual Strategy in a GO2 Foundation Case Study.

Chip Bell, PhD, Customer Service Guru, will deliver tangible examples of What We Can Learn From the Service Industry To Bring Value Back to Patients.

“This has been a time of challenge for patients and care partners, patient organizations, industry, regulators, and our greater society around the world. It is more important than ever to come together to create greater efficiencies and achieve better clinical outcomes for all patients,” said Dr Metcalf, co-chair of the conference.

Additional topics covered include biopharma strategies for applying patient engagement initiatives and demonstrating impact; strategies for increased inclusion of racial and ethnic minorities in clinical trials; progress on patient data ownership; and the next milestones and actions for direct-to-patient clinical trials.

About Patients as Partners US:

Patients as Partners US was established in 2013 as the first conference to demonstrate how patient involvement gets implemented throughout the medicines development life-cycle in order to drive greater efficiencies in getting therapeutics to patients faster.

It is co-produced with patients, industry, academia, government and nonprofit organizations to address the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum.

To learn more about the event, please visit PatientsasPartners.org

About the Conference Forum:

The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.

The Conference Forum presents strategic level conferences, both public and private, as well as developing focus groups and advisory boards for professionals in the life science and healthcare industries. They currently offer conferences for pharma/biotech professionals including R&D leaders, CEOs, business development/licensing, medical affairs/safety, chief patient officers/advocates, clinical innovation champions, investors and drug delivery specialists. The company also publishes six newsletters, reports and produces podcasts.

Learn more about The Conference Forum at theconferenceforum.org.

SCoV-2 Detect IgG ELISA

SEATTLE (PRWEB)
June 11, 2020

InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SCoV-2 Detect IgG ELISA kit, which detects IgG antibodies to SARS-CoV-2 in human serum.

InBios’ COVID-19 antibody test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, the virus that causes COVID-19, which may indicate recent or prior infection. At this time, it is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Antibody testing for COVID-19 is needed to understand the pervasiveness of the disease within communities. The SCoV-2 Detect IgG ELISA kit, which is available to order now, includes all reagents and controls required to run 90 test specimens with results in approximately 2 hours. No specific analyzer is required for this assay, making it versatile and suitable for many qualified laboratories. In performance studies, the kit demonstrates 97.8% sensitivity and 98.9% specificity. InBios has a record of success in bringing high-quality ELISA kits to the world market. In 2011, InBios was the first to be granted a 510(k) clearance from the FDA for its Dengue IgM ELISA kit and offered the first commercial Zika IgM ELISA under FDA’s EUA in 2016. The kits are well established and continue to support accurate diagnostic testing in the US and worldwide.

Dr. Syamal Raychaudhuri, InBios’ chief scientific officer, said, “InBios’ long-term commitment to quality sets us apart as we worked to develop and validate this SARS-CoV-2 antibody test. While we all know speed is of the essence when it comes to diagnostics for emerging diseases like COVID-19, it is equally important to assure that quality and performance allow true insight into who might have an adaptive immune response to this virus.”

InBios offers other products for COVID-19, including the Smart Detect SARS-CoV-2 rRT-PCR Kit, which received an FDA EUA in April. InBios is also developing an ELISA kit for SARS-CoV-2 IgM antibody detection, as well as the SCoV-2 Detect IgM/IgG Rapid Test.

In response to the worldwide pandemic, InBios has ramped up production of its COVID-19 diagnostic tests by increasing production capacity and automation in its state-of-the-art facility in South Lake Union area of Seattle, WA.

While the SCoV-2 Detect IgG ELISA kit has not been FDA cleared or approved, it has been authorized for use by the FDA under an EUA, which permits use of certain medical products that may be effective during a public health emergency, which was declared for COVID-19 on Jan. 31, 2020. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

For more information about InBios COVID-19 tests, visit: http://www.inbios.com/covid-19/.

For more information on COVID-19, please visit http://www.cdc.gov or http://www.who.int.

About InBios: InBios International Inc. specializes in the design, development and manufacture of diagnostic assays for emerging infectious diseases and biothreats. Founded in 1996 in Seattle, WA, InBios offers superior quality products which are accurate, easy to use and cost effective. InBios offers an extensive catalog of life science reagents, along with a portfolio of more than 25 diagnostic products, including the FDA Emergency Use Authorized Smart Detect SARS-CoV-2 rRT-PCR Kit and FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit http://www.inbios.com.

Share article on social media or email:

Hamburg Michigan Podiatrist Foot Doctor Tomasz Biernacki states podiatrists can help with heel pain and plantar fasciitis!

“Patients who let 2-3 months go by can develop difficult to reverse scar tissue and ligament damage that can be more difficult to reverse. This highlights the importance of seeing a podiatrist.”

HAMBURG, Mich. (PRWEB)
June 11, 2020

Dr. Tomasz Biernacki states that “if plantar fasciitis and heel pain are caught early, this can help prevent a condition called plantar fasciosis from developing. This is essentially scar tissue that is exceedingly difficult to reverse. This is when people can develop years of chronic heel pain.”

Dr. Biernacki further states “it is estimated that between 10 to 40% of people around the world will develop chronic crippling heel pain at some point in their life. There are some extremely easy changes to implement such a shoe gear and orthotic changes that don’t have to be expensive and can be very quickly effective.”

The podiatrists and foot doctors at Advanced Foot and Ankle Specialists of Hamburg Michigan have developed a treatment algorithm for diagnosing heel pain. There are six common causes of heel pain that can cause your chronic heel pain. These are plantar fasciitis, Achilles tendinitis, heel stress fractures, fat pad atrophy to the heel, back injuries that can cause nerve pain down to the heel, and finally a bottom of the foot nerve entrapment called Baxter’s nerve compression.

Dr. Tomasz Biernacki is a practicing podiatric foot and ankle surgeon at Advanced Foot and Ankle specialists of Howell Michigan and Brighton Michigan.

Advanced foot and ankle specialists of Howell Michigan and Brighton Michigan pride themselves on providing comprehensive the care and working as a multispecialty team. The four doctors at this practice are on staff at St. Joseph Mercy Hospital Livingston, St. Joseph Mercy Hospital Brighton, and St. Joseph Mercy Hospital Ann Arbor. Working as part of this large multidisciplined team, they can work with internal medicine doctors, primary care doctors, endocrinologists and vascular surgery specialist to provide comprehensive care.

Advanced foot and ankle specialists have four different doctors within their practice: Dr. Tom Biernacki, Dr. John Stevelinck, Dr. Marc Bonanni and Dr. Danielle Meyka-Blanchard. All podiatrists foot doctors are on staff at St. Joseph Mercy hospitals in Ann Arbor, Howell and Brighton Michigan. They pride themselves on serving Livingston County and Washtenaw County.

Share article on social media or email: